Avinash Desai named vice president at Eisai Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AVINASH DESAI was named vice president of Americas Oncology Medical Affairs for the Oncology Business Group of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd.

Desai will lead Eisai’s Oncology Medical Affairs team by creating and overseeing the medical strategy for the Oncology Commercial and Market Access businesses in the Americas. Desai, who has over 20 years of experience in the oncology field, will work closely with the company’s clinical, commercial and OBG strategy organizations to develop, implement and deliver oncology life cycle plans. He will provide strategic leadership to the Medical Affairs team to ensure the delivery of key objectives.

Desai has designed and implemented clinical development and life cycle management plans for a variety of pharmaceutical products, including anti-angiogenic agents, taxanes, proteasome inhibitors, monoclonal antibodies, and targeted therapies. He has served as the global lead of Clinical Development and Medical Affairs teams, and has experience in strategic planning for product development, long-range project and life cycle management strategies, and the development of contingency plans.

Desai joins Eisai from Janssen Pharmaceuticals, Inc., where he was Global Medical Affairs Leader, Oncology responsible for leading the life cycle management of the company’s oncology/hematology products. Prior to Janssen, he was director of International Clinical Development Oncology at Sanofi-Aventis, where he was responsible for the international development of oncology products in solid tumors and hematological malignancies and leading the NDA submission activities for several products. Desai also led the oncology clinical research/medical affairs department at Genaera Corporation.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login